Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths. (fortune.com)
«Our study suggests that whether or not a cancer has this particular abnormality could be a good indicator of its response to immune checkpoint inhibitor drugs.» (sciencedaily.com)
One is a 40 - patient recurrent ovarian cancer study that combines DPX - Survivac with epacadostat, Incyte Corp.'s (INCY: NASDAQ) small - molecule indole 1,2 - dioxygenase checkpoint inhibitor drug. (thelifesciencesreport.com)